Dr. Benjamin Izar, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 16
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 65
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 301965 -
Internal Medicine Physician
MA license L-247883 · NY license 301965
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- New York-Presbyterian Hospital New York, NY
Medical groups
- Trustees of Columbia University in The City of New York (2,296 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 65
- Services billed
- 269
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 91 | 45 |
| Established patient office or other outpatient visit, 30-39 minutes | 38 | 26 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 30 | 14 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 24 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 2 companies reported 7 payments worth $11,008 in total to this clinician.
| Pharming Healthcare, Inc. | $7,613 |
|---|---|
| Immunocore Limited | $3,396 |
| Consulting Fee | $7,613 |
|---|---|
| Honoraria | $2,875 |
| Travel and Lodging | $475 |
| Food and Beverage | $45.85 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pharming Healthcare, Inc. Nov 11, 2025 | Consulting Fee JOENJA · APDS | $5,075 |
| Immunocore Limited May 15, 2025 | Honoraria KIMMTRAK · Oncology | $2,875 |
| Pharming Healthcare, Inc. Jun 10, 2025 | Consulting Fee JOENJA · APDS | $2,538 |
| Immunocore Limited Jun 13, 2025 | Travel and Lodging KIMMTRAK · Oncology · travel to Arlington, VA | $336 |
| Immunocore Limited Jun 13, 2025 | Travel and Lodging KIMMTRAK · Oncology · travel to Arlington, VA | $70.00 |
| Immunocore Limited Jun 13, 2025 | Travel and Lodging KIMMTRAK · Oncology · travel to Arlington, VA | $69.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $156,872 in research payments for these studies, mostly to the institutions running them.
- A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05608291 - A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Sta…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.